Value of Comorbidity Scales for Predicting Survival After Radiochemotherapy of Small Cell Lung Cancer

详细信息    查看全文

• 作者：Lukas Kaesmann ; Stefan Janssen ; Steven E. Schild ; Dirk Rades
• 关键词：Small cell lung cancer ; Radiochemotherapy ; Charlson Comorbidity Index ; MRC Breathlessness Scale ; Survival prognosis
• 刊名：Lung
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：194
• 期：2
• 页码：295-298
• 全文大小：323 KB
• 参考文献：1.Jeremic B, Dobric Z, Casas F (2011) Limited-disease small-cell lung cancer. In: Jeremic B (ed) Advances in radiation oncology in lung cancer, 2nd edn. Springer, Heidelberg, pp 491–506CrossRef
  2.Iachina M, Jakobsen E, Moller H et al (2015) The effect of different comorbidities on survival of non-small cell lung cancer patients. Lung 193:291–297CrossRef PubMed
  3.Firat S, Byhardt RW, Gore E, Radiation Therapy Oncology Group (2002) Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys 54:357–364CrossRef PubMed
  4.Kopek N, Paludan M, Petersen J et al (2009) Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol 93:402–407CrossRef PubMed
  5.Simon TG, Beland MD, Machan JT et al (2012) Charlson Comorbidity Index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation. Eur J Radiol 81:4167–4172CrossRef PubMed
  6.Otake S, Ohtsuka T, Asakura K et al (2016) Impact of comorbidity index on morbidity and survival in non-small cell lung cancer. Asian Cardiovasc Thorac Ann 24:30–33CrossRef PubMed
  7.Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRef PubMed
  8.Charlson M, Szatrowski TP, Peterson J et al (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251CrossRef PubMed
  9.Stenton C (2008) The MRC breathlessness scale. Occup Med (Lond) 58:226–227CrossRef
  10.Colinet B, Jacot W, Bertrand D et al (2005) A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index. Br J Cancer 93:1098–1105CrossRef PubMed PubMedCentral
  11.Gazula A, Baldini EH, Chen A et al (2014) Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer. Lung 192:151–158CrossRef PubMed
  12.Razi SS, Lebovics RS, Schwartz G et al (2010) Timely airway stenting improves survival in patients with malignant central airway obstruction. Ann Thorac Surg 90:1088–1093CrossRef PubMed
  
• 作者单位：Lukas Kaesmann (1)
  Stefan Janssen (1) (2)
  Steven E. Schild (3)
  Dirk Rades (1)
  
  1. Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany
  2. Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany
  3. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Pneumology and Respiratory System
  
• 出版者：Springer New York
• ISSN：1432-1750

文摘

The Charlson Comorbidity Index plus three comorbidity scales were evaluated for survival after radiochemotherapy of limited stage SCLC. For the Charlson Comorbidity Index, 2–4 points were compared to 5–8 points. For the Age-Comorbidity Score, 2–6 points were compared to 7–10 points. For the Medical Research Council (MRC) Breathlessness Scale, grades 0–2 were compared to grades 3–5. For the Simplified Comorbidity Score, 0–5 points were compared to 6–11 and 12–17 points. Charlson Comorbidity Index (p = 0.022) and MRC Breathlessness Scale (p < 0.001) showed significant associations with survival, the Age-Comorbidity Score a trend (p = 0.06). For the Simplified Comorbidity Score, no significant correlation was found (p = 0.54). Absolute differences in survival ≥20 % were observed for the MRC Breathlessness Scale at 1, 2, and 3 years, for the Charlson Comorbidity Index at 1 year, and for the Age-Comorbidity Score at 2 years. Thus, particularly the MRC Breathlessness Scale can contribute to personalization of the treatment of SCLC.